Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10333631 | 0.85 | KMT2A (0.47) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL3978103 | 0.85 | LMNA (0.58) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL29034585 | 0.83 | CYP1A2 (0.49) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL342714 | 0.81 | KMT2A (0.56) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL344099 | 0.81 | KMT2A (0.56) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL4077813 | 0.80 | KMT2A (0.55) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL14813157 | 0.80 | KMT2A (0.51) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL28560305 | 0.80 | KMT2A (0.46) | CYP1A2KMT2AMEN1GAAESR1 | |
| SCHEMBL30828333 | 0.80 | CA12 (0.46) | CYP1A2KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL6942034 | 0.80 | GAA (0.50) | CYP1A2KMT2AMEN1GAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| EP-4122499-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| EP-1817037-B1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8101754-B2 | e.g., 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-(1-methylcyclopropyl)-pyrimidine hydrochloride; central nervous system disorders; schizophrenia; antidepressant, anxiolytic agent, cognition activator; Parkinson's and Alzheimer's diseases | ABBOTT GMBH & CO. KG (DE) | 2012-01-24 | — | — | US | disclosed |
| US-7943779-B2 | Process for the preparation of olmesartan medoxomil | KRKA (SI) | 2011-05-17 | — | — | US | disclosed |
| US-7183292-B2 | Substituted pyrrolidine and related compounds | THERAVANCE, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ADRB3, DRD3, ADORA3 | CYP1A2 348/4885KMT2A 3677/4885MEN1 2438/4885 |
| US-20040254219-A1 | Substituted pyrrolidine and related compounds | CHRM1, CHRM5, ADRA1D | CYP1A2 514/4885KMT2A 3243/4885MEN1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.